- Research article
- Open Access
- Open Peer Review
Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflation for control of malignant pleural effusions: a review of 400 cases
© Barbetakis et al; licensee BioMed Central Ltd. 2010
- Received: 19 December 2009
- Accepted: 19 April 2010
- Published: 19 April 2010
Malignant pleural effusion is a common sequelae in patients with certain malignancies. It represents a terminal condition with short median survival (in terms of months) and the goal is palliation. Aim of our study is to analyze morbidity, mortality and life expectancy following videothoracoscopic talc poudrage.
Materials and methods
From September 2004 to October 2009, 400 patients underwent video-assisted thoracic surgery (VATS) for malignant pleural effusion. The conditions of patients were assessed and graded before and after treatment concerning morbidity, mortality, success rate of pleurodesis and median survival.
The median duration of follow up was 40 months (range 4-61 months). All patients demonstrated notable improvement in dyspnea. Intraoperative mortality was zero. The procedure was well tolerated and no significant adverse effects were observed. In hospital mortality was 2% and the pleurodesis success rate was 85%. A poor Karnofsky Performance Status and delay between diagnosis of pleural effusion and pleurodesis were statistically significant factors for in-hospital mortality. The best survival was seen in breast cancer, followed by ovarian cancer, lymphoma and pleural mesothelioma.
Video-assisted thoracoscopic talc poudrage is an effective and safe procedure that yields a high rate of successful pleurodesis and achieves long-term control with marked dyspnea decrease.
- Pleural Effusion
- Pleural Fluid
- Malignant Pleural Effusion
- Chemical Pleurodesis
Pleural effusions are a common and devastating complication of advancedmalignancies. These effusions most commonly occur with lung, breast, ovarian cancer and lymphoma, with breast and lung malignancies alone accounting for approximately of 75% of these effusions .
In patients who develop progressive pleural effusions producing dyspnea and cough, quality of life is affected. Patients with symptomatic effusions may benefit from pleurodesis to relieve dyspnea and to prevent reaccumulation of pleural fluid.
The purpose of this study was to determine the long term efficacy and safety of pleurodesis by thoracoscopic talc poudrage in malignant pleural effusions.
All patients with symptomatic malignant pleural effusion referred to the Thoracic Surgery service of Theagenio Cancer Hospital for thoracoscopic pleurodesis were eligible to participate in this study. Inclusion in the study required documentation of a malignant pleural effusion and good general condition (capability to care for themselves). The diagnosis of pleural carcinomatosis was established by positive pleural fluid cytology on thoracentesis or evidence of malignancy on pleural biopsy prior to referral. Patients with significant loculated effusions or trapped lung after drainage were excluded from the study. All patients underwent preoperative bronchoscopy to exclude endobronchial obstruction and chest computed tomography scan.
Thoracoscopy was performed under general anesthesia in all patients. A 10-mm camera port and one or two instrumentation ports were inserted. We used a zero grade optical camera to assess the pleura and the lung surface. The pleural effusion was carefully aspirated and fibrinous adhesions were divided with diathermy. At least four different biopsy specimens were obtained from abnormal areas and a frozen section was performed. The degree of lung expansion was ascertained with sustained positive pressure ventilation (20-30 cm H2O). Pleurodesis was performed by thoracoscopic insufflation of sterile asbestos-free talc powder (6 gr) in all patients regardless the extent of disease. At the end of the procedure one chest tube was left in situ. The drain was removed when the volume collected remained under 200 ml for two consecutive days.
Morbidity included all complications occurring during hospitalization only. In-hospital mortality included both those patients who died within first 30 days and those who died later but during the same hospitalization. Three-month mortality included those patients who died within 90 days after surgery. Follow up was obtained by periodical clinical examination combined with chest radiography and/or thoracic ultrasound. The failure of pleurodesis was defined by a need for repeat thoracentesis or tube thoracostomy to drain a recurrent pleural effusion during the 3 months after pleurodesis.
Univariate analysis was used for continuous variables associated with In-Hospital mortality and 3-Month Mortality. Data are mean ± standard deviation. Differences were considered significant with p values of p < 0.05.
The study was approved by the Investigational Review Board at Theagenio Cancer Hospital and informed consent was obtained from all eligible patients.
Characteristics of the study population (n: 400).
Weight loss > 5 kg
Pathology of 400 malignant pleural effusions.
Non small cell lung cancer
Small cell lung cancer
Parotid gland cancer
The average duration of VATS talc pleurodesis combined with pleural or lung biopsies was 26 minutes (± 6 min). The conversion rate to thoracotomy was 0%. No operative deaths and no intraoperative major complications were occurred. Three hundred and ninety three patients were weaned from mechanical ventilation in the operating theatre. Seven patients were transferred intubated to the intensive care unit.
Complications in 400 patients with malignant pleural effusion and thoracoscopic talc poudrage performed.
Prolonged air leak
Acute respiratory failure
Persistent pleural space
Tumor recurrence at port site
Reexpansion pulmonary edema
The average duration of chest drainage was 6 days (range: 2 - 10). The average duration of postoperative hospitalization was 7 days (range: 4 - 9) for the patients without postoperative complications versus 16 days (range: 7 - 40) for the patients with postoperative complications.
Continuous variables associated with In-Hospital mortality and 3-Month Mortality in Univariate Analysis.
In hospital mortality
61 ± 16
69 ± 14
60 ± 14
71 ± 13
74 ± 14
60 ± 18*
76 ± 18
60 ± 16*
Delay between diagnosis and pleurodesis (days)
40 ± 16
66 ± 36*
45 ± 16
78 ± 60*
Average survival following pleurodesis according to primary malignancy.
Average survival (months)
Parotid gland cancer
Non small cell lung cancer
Small cell lung cancer
Success rate, 3 and 6 months following thoracoscopic talc pleurodesis.
Success Rate after 3 months (340/400) [85%]
Success Rate after 6 months (328/400) [82%]
Non small cell lung cancer
Small cell lung cancer
Parotid gland cancer
Death with no recurrence
Malignant pleural effusions are one of the leading causes of recurrent pleural effusions worldwide, with an estimated annual incidence of 150.000 cases in the United States . Dyspnea that arises from pleural effusion impacts considerably the quality of life. Thoracentesis is an essential first step but may only provide temporary relief and can be associated either with the recurrence of pleural effusion (90% of patients will develop recurrence of effusion within 30 days) or to iatrogenic pneumothorax, pleural fluid loculation or contamination with subsequent empyema . Simple chest tube drainage is also associated with recurrence of pleural effusion (80% of patients within 30 days after removal of the tube) . Chest tube drainage and chemical pleurodesis is the gold standard of care for malignant pleural effusions. Tetracycline the agent used most commonly in the past, is no longer commercially available. Many other chemotherapeutic agents such as doxorubicin, cisplatin and cytarabine combination, etoposide, fluorouracil, mitomycin, mitoxantrone have been used for sclerotherapy. In addition radioactive isotopes, corynebacterium parvum, interferon and recombinant interleukin-2 have been instilled in the pleural space for treatment of malignant pleural effusions. Response rate has been variable and less than optimal .
Silver nitrate 0.5% has proved to be an efficient alternative to tetracycline derivatives and talc for inducing pleurodesis in experimental studies. Its efficacy has also been proved in clinical studies. In patients with malignant pleural effusions who received 0.5% silver nitrate or 5 g of talc "slurry," silver nitrate was more effective in inducing pleurodesis after a 1-month evaluation (95.6% vs 87.5%) and had no significant adverse systemic effects .
Over the last decade, indwelling pleural catheter drainage has established itself as a less expensive, minimally invasive, and palliative modality for the management of malignant pleural effusions. Dozens of recent publications on its utility and efficacy for the long-term management of these effusions have increased its popularity as an alternative to conventional modalities .
Talc ([Mg3Si4]O10 [OH]2) is a trilayered magnesium sheet silicate. Preparations historically have had some minimal associated impurities, most notably asbestos. Talc can be used during thoracoscopy or thoracotomy, or as a slurry via thoracostomy. Chambers using talc slurry in 1958, was the first to utilize talc for the treatment of malignant pleural effusions .
Video-assisted thoracoscopy with talc poudrage has replaced conventional instillation of talc slurry through tube thoracostomy as the painless procedure of choice to achieve pleurodesis. It also offers the advantage of complete evacuation of the pleural cavity and visualization of the pleural surface allowing multiple biopsies to be performed with very high accuracy. Futhermore, adhesions may be broken up with confirmation of complete lung reexpansion. This method also permits the distribution of talc in a uniform manner, even in the most inaccessible areas with acceptable morbidity as shown in our study. On the other hand, other investigators advocate that talc slurry instillation is the procedure of choice for patients with symptomatic malignant pleural effusions without trapped lungs due to cost-effectiveness . In our institution, chemical pleurodesis by instillation of asbestos-free talc is strongly recommended in patients with poor Karnofsky Performance Status with an expected median survival of less than 3 months.
In our series in-hospital mortality was 2%, approximately the same with other series [10, 11]. The mortality rate within 3 months was 3.7%, with Karnofsky Performance Status and delay between diagnosis of pleural effusion and pleurodesis to play a statistically significant role. According to the international literature there is a credible possibility that aggressive diseases are responsible for a rapid and plentiful recurrence of pleural effusion and limited life expectancy. Sahn and Good showed that this type of pleural effusion correlated with a pH of 7.28 or less or with a lower glucose concentration . Rodriguez-Panadero and Lopez-Mejias also suggested that the extent of pleural lesions detected during thoracoscopy was closely related to both glucose and hydrogen ion concentrations in pleural fluid and that duration of survival was inversely related to the extent of carcinomatous involvement of the pleura . These pleural fluid characteristics were not examined in our study.
The failure rate of videothoracoscopic talc pleurodesis was 15% and is higher compared to other series reported, with a range of failure rate from 0% to 7% [11, 14, 15]. The possible explanation is that it is difficult to compare our data with other series; the characteristics of our patients are different as well as the primary malignancies.
There are however, potential limitations to our study. The retrospective study design could have introduced systemic bias, including patients who were unavailable for follow up. This problem was eliminated by using data that were derived from a 90- and 180-day period with complete outcome information for statistical analysis. Furthermore the quality of life was not documented in the months following the procedure. Successful pleurodesis is linked to marked improvement in dyspnea. However the patient benefit regarding quality of life still remains to be elucidated.
In conclusion videothoracoscopic talc poudrage represents a safe and reliable method to obtain pleurodesis in patients with malignant recurrent pleural effusion non-responding to corticosteroid therapy and or to chemotherapy. The long-term results show a high successful rate. A more effective pleurodesis is likely, if videothoracoscopic talc poudrage is performed early after the diagnosis and the lung is free to reexpand.
- Lynch TJ: Management of pleural effusions. Chest. 1993, 103: 385-389.View ArticleGoogle Scholar
- American Thoracic Society: Management of malignant pleural effusions. Am J Respir Crit Care Med. 2000, 162: 1987-2001.View ArticleGoogle Scholar
- Cardillo G, Facciolo F, Carbone L, Regal M, Corzani F, Ricci A, Di Martino M, Martelli M: Long-term follow up of video-assisted talc pleurodesis in malignant recurrent pleural effusions. Eur J Cardiothorac Surg. 2002, 21: 302-306. 10.1016/S1010-7940(01)01130-7.View ArticlePubMedGoogle Scholar
- Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G: Use of small-bore versus large-bore chest tubes for treatment of malignant pleural effusions. Chest. 2001, 120: 19-25. 10.1378/chest.120.1.19.View ArticlePubMedGoogle Scholar
- Barbetakis N, Antoniadis T, Tsilikas C: Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. World Journal of Surgical Oncology. 2004, 2: 16-10.1186/1477-7819-2-16.View ArticlePubMedPubMed CentralGoogle Scholar
- Marchi E, Vargas FS, Teixeira LR, Acencio MMP, Antonangelo L, Light RW: Intrapleural Low-Dose Silver Nitrate Elicits More Pleural Inflammation and Less Systemic Inflammation Than Low-Dose Talc. Chest. 2005, 128: 1798-1804. 10.1378/chest.128.3.1798.View ArticlePubMedGoogle Scholar
- Musani AI: Treatment options for malignant pleural effusion. Current Opinion in Pulmonary Medicine. 2009, 15: 380-387. 10.1097/MCP.0b013e32832c6a8a.View ArticlePubMedGoogle Scholar
- Chambers JS: Palliative treatment of neoplastic pleural effusions with intercostals intubation and talc instillation. West J Surg Obstet Gynecol. 1958, 66: 26-28.PubMedGoogle Scholar
- Yim A, Chan ATC, Wai Lee T, Wan IYP, Ho JKS: Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg. 1996, 62: 1655-1658. 10.1016/S0003-4975(96)00808-9.View ArticlePubMedGoogle Scholar
- Bernard A, de Dompsure RB, Hagry A, Favre JP: Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg. 2002, 74: 213-217. 10.1016/S0003-4975(02)03599-3.View ArticlePubMedGoogle Scholar
- Schulze M, Boehle AS, Kurdow R, Dohrmann P, Henne-Bruns D: Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients. Ann Thorac Surg. 2001, 71: 1809-1812. 10.1016/S0003-4975(01)02586-3.View ArticlePubMedGoogle Scholar
- Sahn SA, Good JT: Pleural fluid pH in malignant effusion: diagnostic, prognostic and therapeutic implications. Ann Intern Med. 1988, 108: 345-347.View ArticlePubMedGoogle Scholar
- Rodriguez-Panadero F, Lopez-Mejias J: Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. Chest. 1989, 95: 320-324. 10.1378/chest.95.2.320.View ArticlePubMedGoogle Scholar
- Furedi A, Keekes L, Gether P, Kiss B: Video-assisted thoracoscopic talc pleurodesis for malignant pleural effusions. Acta Chir Hung. 1999, 38: 155-157.PubMedGoogle Scholar
- Milanez de Campos R, Vargas FS, de Campos Werebe E: Thoracoscopy talc poudrage. A 15-year experience. Chest. 2001, 119: 801-806. 10.1378/chest.119.3.801.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.